Trials / Completed
CompletedNCT02369016
Phase III Copanlisib in Rituximab-refractory iNHL
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety of copanlisib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Copanlisib (BAY 80-6946) | 60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle |
Timeline
- Start date
- 2015-09-22
- Primary completion
- 2022-10-26
- Completion
- 2022-10-26
- First posted
- 2015-02-23
- Last updated
- 2023-11-18
- Results posted
- 2023-11-18
Locations
21 sites across 10 countries: Brazil, Bulgaria, Greece, Italy, Poland, Russia, South Africa, South Korea, Taiwan, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT02369016. Inclusion in this directory is not an endorsement.